Agios Pharmaceuticals (AGIO) Receivables - Other (2013 - 2026)

Agios Pharmaceuticals has reported Receivables - Other for 14 years, with the latest figure at $16.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 382.42% year-over-year to $16.1 million; the trailing twelve-month figure through Mar 2026 stood at $16.1 million (up 382.42% YoY), and the FY2025 full-year result was $10.6 million, up 157.41% from the prior year.
• Receivables - Other for Q1 2026 stood at $16.1 million, up from $10.6 million in the prior quarter.
• The five-year high for Receivables - Other was $16.1 million in Q1 2026, with the low at $540000.0 in Q1 2022.
• Historically, Receivables - Other has averaged $4.0 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Other tumbled 80.35% — and 2026, when it surged 382.42%.
• Agios Pharmaceuticals' Receivables - Other stood at $2.2 million in 2022, then increased by 27.38% to $2.8 million in 2023, then jumped by 46.23% to $4.1 million in 2024, then jumped by 157.41% to $10.6 million in 2025, then soared by 52.52% to $16.1 million in 2026.
• The last three Receivables - Other figures came in at $16.1 million (Q1 2026), $10.6 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.